,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu', 'daiichi']
oncologists can celebrate like football fans too! showing data from a breakthrough breast cancer drug enhertu, developed by and at #asco22. patients on enhertu lived 7 months longer than on standard chemo. 
@RyvuTx CEO, @SelvitaKrakow and @Ardigen_SA co-founder, ex. @Comarch and https://t.co/HuuMtVdzI9. Private opinions.